Babler Martin — SEC Form 4 filings
SEC reporting owner CIK 1435618. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-25.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-05-03 to 2026-06-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 15,650 shares, $100,733 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: purchase of 15,650 shares @ $6.44 ($100,733) in ALUMIS INC., filed 2025-04-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALUMIS INC. (ALMS) | President, CEO and Chairman, Director | 5 | 1 leg · 15,650 sh · $100,733 | — | 25 |
| 89bio, Inc. (ETNB) | Director | 3 | — | — | 4 |
| Prelude Therapeutics Inc (PRLD) | Director | 3 | — | — | 3 |
| MapLight Therapeutics, Inc. (MPLT) | Director | 1 | — | — | 2 |
Form 4 filings — Babler Martin
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-25 | 4 | MapLight Therapeutics, Inc. (MPLT) | Grant/award (A): 7,864 @ $0 · Grant/award (A): 29,804 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | ALUMIS INC. (ALMS) | Grant/award (A): 745,875 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Disposition to issuer (D): 67,700 (derivative) @ $0 · Disposition to issuer (D): 56,400 (derivative) @ $0 | EDGAR |
| 2025-07-31 | 4 | ALUMIS INC. (ALMS) | Grant/award (A): 662,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 15,650 @ $6.44 | EDGAR |
| 2025-02-20 | 4 | ALUMIS INC. (ALMS) | Grant/award (A): 523,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 56,400 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | ALUMIS INC. (ALMS) | Disposition to issuer (D): 90,804 · Grant/award (A): 90,804 · Grant/award (A): 21,390 (derivative) @ $0 · Disposition to issuer (D): 21,390 (derivative) @ $0 · Grant/award (A): 21,390 (derivative) @ $0 · Disposition to issuer (D): 380,852 (derivative) @ $0 · +15 more | EDGAR |
| 2024-06-18 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 23,500 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 67,700 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1435618 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →